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CASE REPORT 
Small bowel perforation secondary to intestinal 
tuberculosis in patient with chronic idiopathic 
myelofibrosis 
Mohamed Shafi, Ikhwan Sani Mohamad, Wan Mokhzani Wan Mokhter, Siti Rahmah Hashim Merican, 
Zaidi Zakaria, Nik Fatin Amirah Nik Min, Faezahtul Arbaeyah Hussain 
Idiopathic myelofibrosis is a myeloproliferative disorder in which 
blood cell development is abnormal. It causes scarring and fibrotic 
changes in the bone marrow. Also known as primary myelofibrosis 
(PMF), this condition is usually chronic and progressive. The exact 
causative factor is not clear but scientists found that the condition is 
typically characterized by the mutations in Janus Kinase 2(JAK2) 
gene. Clinical features of PMF include progressive anemia, 
symptomatic splenomegaly, and other constitutional symptoms. 
PMF is associated with a poor prognosis and a marked reduction in 
life expectancy, with median survival ranging from 3.5 to 6 years. 
There have been reports on the coexistence of PMF with other 
granulomatous diseases such as tuberculosis. It was reported that 
the incidence of tuberculosis is much higher in patients having PMF 
compared to the normal population. PMF is commonly treated with 
JAK2 inhibitor (Ruxolitinib) and prednisolone. Several case reports 
have shown that PMF treatment may lead to opportunistic infections, 
such as tuberculosis. We would like to report a case of small bowel 
tuberculosis flare-up by patients of chronic idiopathic myelofibrosis 
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INTRODUCTION 
Idiopathic myelofibrosis is a clonal 
hematopoietic stem cell disorder due to a 
mutation in the signaling regulator gene JAK2. 
The condition is widely treated with 
Ruxolitinib which is a JAK2 inhibitor along with 
prednisolone. The only curative treatment 
available till now is allogeneic haematopoietic 
stem cell transplant.1 Ruxolitinib with 
prednisolone despite promising has been 
linked with the risk of opportunistic infections 
and reactivation of tuberculosis.2We herein 
report a patient with chronic idiopathic 
myelofibrosis who developed small bowel 
perforations secondary to the flare-up of gut 
tuberculosis. 
CASE REPORT  
A 57-year-old Malay ethnicity male which was 
diagnosed with primary myelofibrosis since 
2014 and under regular haematology follow up 
was referred to the general surgery 
department for acute onset of generalized 
abdominal pain. The patient has an underlying 
history of Pulmonary Tuberculosis (TB) and has 
completed treatment about ten years ago. He 
claimed that he was on anti TB drugs for about 
six months and was tested negative after 
completion of the therapy. The rest of the 
family members were screened negative 
otherwise. The patient gave a history of loss of 
weight and appetite with persistent lethargy 
and poor oral intake for the past two months. 
He has been receiving treatment from the 
haematology department ever since he was 
diagnosed with PMF. His JAK2 status was 
negative while the peripheral blood film 
showed borderline bicytopaenia with 
leucoerythroblastic picture and occasional 
suspicious mononuclear cells. Bone marrow 
trephine biopsy confirmed the diagnosis of 
myelofibrosis (in cellular phase). The patient 
arrived at the emergency department with 
signs of hypotension and prompt resuscitation 
measures were taken while arrangement for 
an urgent chest and abdominal x-rays were 
ongoing. The initial chest x-ray showed air 
under the diaphragm and the patient was 
rushed to the operating room with the 
diagnosis of perforated gastric ulcer (Figure 1). 
Upon entering the abdomen noted that there 
were copious collections with small bowel 
adhesions especially at the ileum (Figure 2). A 
segment of the small bowel (ileum) was noted 
to have multiple perforations (three 
perforations each measuring 2-4mm in 
diameter) with content leakage. Segmental 
bowel resection (about 10cm in length), 
double-barrel stoma with peritoneal lavage 
was performed. The peritoneal collections 
were sampled for culture and sensitivity and 
acid-fast staining. Resected bowel segment 
HPE came out as perforated granulomatous 
ileitis secondary to mycobacterium infection 
(figure 3 and 4). Peritoneal fluid acid-fast 
staining showed negative for Mycobacterium 
while the culture and sensitivity showed mixed 
growth. The patient was subsequently started 
on anti-TB medications and was put under 
direct supervision therapy. With our latest 
follow up, the patient was doing well with no 
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Figure 3 (Hematoxylin and eosin, 40x magnification) showing granuloma formation composed of 
 epithelioid cells (arrowhead) with oval to elongated nuclei and abundant eosinophilic 
 cytoplasm, surrounded by mature lymphocytes and histiocytes collection. Langerhans 













Figure 4 (Ziehl- Neelsen staining 100x magnification) Numerous scattered magenta coloured, 
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DISCUSSION 
Primary Myelofibrosis is a myeloproliferative 
monoclonal disorder characterized by 
extensive bone marrow fibrosis. Till the 
present day, treatment for PMF is using 
Ruxolitinib, a JAK 2 inhibitor along with other 
newer drugs.3-4 Curative treatment is by using 
allogeneic haematopoietic stem cell 
transplant with a five-year survival rate.5 
Nonetheless, treatment for PMF has been 
linked with the risk of weakening host 
immunity and opportunistic infections.6 
Tuberculosis is a granulomatous infection with 
the hallmark of caseating necrosis that can be 
found in both pulmonary and extra pulmonary 
regions. The case that we encountered showed 
that patients with PMF on treatment have a 
high probability to get a flare-up of 
tuberculosis be it pulmonary or extra 
pulmonary. Despite being JAK2 negative, the 
patient has been prescribed with long term 
steroids since 2014 by the haematology unit. 
He was offered with allogenic stem cell bone 
marrow transplant which the patient refused. 
Asymptomatic patients usually do not need 
treatment. Treatment is subjected to patients 
to improve their quality of life and to manage 
the ongoing complications. We would like to 
establish a link between PMF and TB and the 
potential flare-up of tuberculosis that might 
occur in such patients.7 Interestingly extra 
pulmonary tuberculosis flare-up in PMF has 
never been reported before. The coexistence 
of PMF and TB has been documented decades 
ago.8 Besides myeloproliferative disease itself, 
the treatment may potentiate granulomatous 
infection in the host. As per this case, the 
patient has a history of pulmonary TB some ten 
years ago. It is well known that mycobacterium 
may remain dormant for many years in the host 
before reactivation.9 We would also like to 
highlight the importance of strengthening the 
host immunity once been diagnosed with 
myeloproliferative disease. As per today, the 
only curative treatment available is allogeneic 
stem cell bone marrow transplant.10 The 
patient in this case succumbed to the 
complications of extra pulmonary tuberculosis 
flare up secondary to the myeloproliferative 
disease and its treatment. It is a challenge to 
the treating physician as well as to the patient 
diagnosed with myeloproliferative disease to 
endure the uncertainty of the course of the 
disease. With the reported case above, we 
should be vigilant in dealing with patients with 
myeloproliferative disease and the 
complications of the current treatment 
modalities and definitely to be aware of 
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